DE69927262D1 - Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren - Google Patents

Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren

Info

Publication number
DE69927262D1
DE69927262D1 DE69927262T DE69927262T DE69927262D1 DE 69927262 D1 DE69927262 D1 DE 69927262D1 DE 69927262 T DE69927262 T DE 69927262T DE 69927262 T DE69927262 T DE 69927262T DE 69927262 D1 DE69927262 D1 DE 69927262D1
Authority
DE
Germany
Prior art keywords
composition
tumors
peptides
fab
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69927262T
Other languages
English (en)
Other versions
DE69927262T2 (de
Inventor
Cornelis J M Melief
Rienk Offringa
Rene Toes
Stephen P Schoenberger
Boer Mark De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leids Universitair Medisch Centrum LUMC
Tanox Inc
Original Assignee
Leids Universitair Medisch Centrum LUMC
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leids Universitair Medisch Centrum LUMC, Tanox Inc filed Critical Leids Universitair Medisch Centrum LUMC
Publication of DE69927262D1 publication Critical patent/DE69927262D1/de
Application granted granted Critical
Publication of DE69927262T2 publication Critical patent/DE69927262T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69927262T 1998-05-23 1999-05-21 Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren Expired - Lifetime DE69927262T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8662598P 1998-05-23 1998-05-23
US86625P 1998-05-23
PCT/US1999/011419 WO1999061065A1 (en) 1998-05-23 1999-05-21 Cd40 binding molecules and ctl peptides for treating tumors

Publications (2)

Publication Number Publication Date
DE69927262D1 true DE69927262D1 (de) 2006-01-26
DE69927262T2 DE69927262T2 (de) 2006-04-27

Family

ID=22199819

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69927262T Expired - Lifetime DE69927262T2 (de) 1998-05-23 1999-05-21 Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren
DE69941165T Expired - Lifetime DE69941165D1 (de) 1998-05-23 1999-05-21 CD40 bindende Moleküle und CTL Peptide zur Behandlung von Tumoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69941165T Expired - Lifetime DE69941165D1 (de) 1998-05-23 1999-05-21 CD40 bindende Moleküle und CTL Peptide zur Behandlung von Tumoren

Country Status (11)

Country Link
US (2) US7563445B2 (de)
EP (2) EP1616579B1 (de)
JP (1) JP4927254B2 (de)
CN (2) CN1762492A (de)
AT (1) ATE304375T1 (de)
AU (1) AU765822B2 (de)
DE (2) DE69927262T2 (de)
DK (2) DK1082141T3 (de)
ES (2) ES2330017T3 (de)
NZ (1) NZ508831A (de)
WO (1) WO1999061065A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061065A1 (en) * 1998-05-23 1999-12-02 Leiden University Medical Center Cd40 binding molecules and ctl peptides for treating tumors
US6680176B2 (en) 1999-05-17 2004-01-20 The United States Of America, As Represented By The Department Of Health And Human Services Identification of candidate ligands which modulate antigen presenting cells
US20030118588A1 (en) * 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
WO2001015728A1 (en) * 1999-08-27 2001-03-08 University Health Network Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen
BR0108001A (pt) * 2000-02-01 2004-01-06 Tanox Inc Moléculas ativadoras de apc com ligação para cd-40
AU2001241918A1 (en) 2000-03-02 2001-09-12 Med Immune, Inc. Methods of enhancing activity of vaccines and vaccine compositions
AU2006236905B2 (en) * 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006128103A2 (en) * 2005-05-26 2006-11-30 Seattle Genetics, Inc. Humanized anti-cd40 antibodies and their methods of use
MX2008013993A (es) 2006-05-03 2009-05-11 Univ Colorado Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
GB0703976D0 (en) * 2007-03-02 2007-04-11 Adjuvantix Ltd Liposome preparation
CA2996732C (en) 2007-03-26 2020-10-27 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Prame derived peptides and immunogenic compositions comprising these
CA2692652C (en) 2007-05-31 2018-10-23 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
AU2008257791B2 (en) 2007-05-31 2013-03-28 Academisch Ziekenhuis Leiden H.O.D.N. Lumc P53 peptide vaccine
CA2688589A1 (en) 2007-05-31 2008-12-31 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Intradermal hpv peptide vaccination
WO2010024676A1 (en) * 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
GB2478283A (en) * 2010-03-01 2011-09-07 Nissan Motor Mfg Vehicle occupant restraint control apparatus
WO2012026820A2 (en) 2010-08-27 2012-03-01 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
EP2471543A1 (de) 2010-12-02 2012-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Toleranzinduktion oder Immunsuppression zur Verhinderung von insbesondere Transplantat-Wirt-Reaktion (GvHD) durch kurzzeitige Vorinkubation von transplantierten Zellsuspensionen, Geweben oder Organen, die mit Liganden zu Zelloberflächenmolekülen beschichtet sind
WO2013006050A1 (en) 2011-07-06 2013-01-10 Isa Pharmaceuticals B.V. Peptides inducing or enhancing an immune response against prostate-specific membrane protein (PSMA)
EP2687849A1 (de) 2012-07-20 2014-01-22 ISA Pharmaceuticals B.V Verfahren zur Bereitstellung einer optimierten Immuntherapiezusammensetzung
EP3148566B1 (de) 2014-06-02 2024-04-03 ISA Pharmaceuticals B.V. Synthetische, lange peptide (slp) zur therapeutischen impfung gegen hepatitis-b-virusinfektion
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
US10702598B2 (en) 2016-06-20 2020-07-07 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
WO2018197949A1 (en) 2017-04-27 2018-11-01 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
EP3847187A1 (de) 2018-09-03 2021-07-14 Laboratoire HRA-Pharma Zp3-fragmente in der immuntherapie von eierstockkrebs
KR20210098450A (ko) 2018-10-31 2021-08-10 주노 테라퓨틱스 게엠베하 세포의 선택 및 자극을 위한 방법 및 이를 위한 장치
WO2020097132A1 (en) 2018-11-06 2020-05-14 Juno Therapeutics, Inc. Process for producing genetically engineered t cells
KR20220101641A (ko) 2019-10-30 2022-07-19 주노 테라퓨틱스 게엠베하 세포 선택 및/또는 자극 장치 및 사용 방법
US20230087422A1 (en) 2020-02-07 2023-03-23 Isa Pharmaceuticals B.V. Treatment of hpv-related diseases
CN115835873A (zh) 2020-05-13 2023-03-21 朱诺治疗学股份有限公司 用于产生表达重组受体的供体分批细胞的方法
EP4334341A2 (de) 2021-05-06 2024-03-13 Juno Therapeutics GmbH Verfahren zur stimulierung und transduktion von t-zellen
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
WO2024161021A1 (en) 2023-02-03 2024-08-08 Juno Therapeutics Gmbh Methods for non-viral manufacturing of engineered immune cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
NZ273504A (en) * 1993-10-01 1997-12-19 Immunex Corp Monoclonal antibodies (moabs) that specifically bind human cd40 molecules and cd40 ligand binding
NZ305083A (en) * 1995-03-01 1999-06-29 Immunex Corp Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response
AU738649B2 (en) * 1996-04-26 2001-09-20 Rijksuniversiteit Te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
WO1999061065A1 (en) * 1998-05-23 1999-12-02 Leiden University Medical Center Cd40 binding molecules and ctl peptides for treating tumors

Also Published As

Publication number Publication date
ES2249907T3 (es) 2006-04-01
CN1762492A (zh) 2006-04-26
EP1082141A1 (de) 2001-03-14
EP1616579A1 (de) 2006-01-18
CN1212155C (zh) 2005-07-27
JP4927254B2 (ja) 2012-05-09
WO1999061065A1 (en) 1999-12-02
DE69941165D1 (de) 2009-09-03
AU765822B2 (en) 2003-10-02
NZ508831A (en) 2004-08-27
CN1346284A (zh) 2002-04-24
ATE304375T1 (de) 2005-09-15
US20090285814A1 (en) 2009-11-19
US7563445B2 (en) 2009-07-21
EP1082141B1 (de) 2005-09-14
US20030022860A1 (en) 2003-01-30
JP2002528383A (ja) 2002-09-03
DK1082141T3 (da) 2005-12-05
EP1616579B1 (de) 2009-07-22
EP1082141A4 (de) 2002-08-07
DE69927262T2 (de) 2006-04-27
ES2330017T3 (es) 2009-12-03
AU4311299A (en) 1999-12-13
DK1616579T3 (da) 2009-09-14

Similar Documents

Publication Publication Date Title
DE69927262D1 (de) Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren
ATE483733T1 (de) Hochaffine humane antikörper gegen tumorantigene
ATE303161T1 (de) Humanisierung von anti-carcinoembryonalen antigen anti-idiotypischen antikörper und dessen verwendung als tumorvakzin und zur markierung
ATE213507T1 (de) Methode zur bindung von material an das beta- amyloid-peptid
HK1091499A1 (en) Methods for preventing and treating alzheimers disease (ad) (ad)
ATE535254T1 (de) Behandlung von krebs mit dem anti-erbb2- antikörper rhumab 2c4
CO5580797A2 (es) Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos
ATE478944T1 (de) Zytokin ligand zur behandlung von asthma und atemwegsüberreaktivität
LU92596I2 (fr) Vedolizumab et ses variantes thérapeutiquement équivalentes, comme protégées par le brevet de base, notamment vedolizumab
ATE549347T1 (de) Gene von säugetiere, und damit verbundene reagentien, methoden
ATE510851T1 (de) Auf peptiden basierende immunisierungstherapie zur behandlung von atherosklerose
DE69532588D1 (de) Verfahren zur verbesserung der immunogenität einer immunogenen zusammensetzung oder eines haptens und verwendung zur herstellung von impfstoffen
FR2660757B1 (fr) Procede d'identification ou de dosage de proteines et applications.
DE69840509D1 (de) Apoptose-bezogene verbindungen und deren verwendung
ATE495751T1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
WO1995021922A3 (en) Non-a, non-b, non-c, non-d, non-e hepatitis reagents and methods for their use
ATE94880T1 (de) Synthetische peptide, gegen diese gerichtete antikoerper und deren verwendung.
ATE285418T1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
DE60231475D1 (de) Materialien und methoden zur behandlung von hepatitis c
ATE290881T1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
ATE449171T1 (de) Reagentia und verfahren zum nachweis von brustkrankheiten
DE69617255D1 (de) Durch hla-b44 moleküle präsentierte tumor-abstossungsantigene und ihre verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition